[Prevention of congenital toxoplasmosis with spiramycin; value and limits of levels in amniotic fluid].
Bourget
P
P
Lesne-Hulin
A
A
Forestier
F
F
Desmaris
V
V
Dulac
E
E
D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D015572:Spiramycin / Q000032:analysis / Q000627:therapeutic use*; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D015572:Spiramycin
Prévention de la toxoplasmose congénitale par la spiramycine; intérêt et limites du dosage dans le liquide amniotique.